Here is the updated math, and anyone can suggest corrections Soon QuestCap should have about 45 testing sites up and running. So, we will use the 7-day rolling average of 94 tests per day per site and an average test price of $95 per test; I used these numbers from the QuestCap guidance. https://www.youtube.com/watch?v=w4aLyWBeZKY&feature=youtu.be
These 45 testing sites perform 45x94=4230 tests each day, and revenue is 4230x$95=$401,850 each day. Now, we calculate $401,850x30=$12,055,500 per month. These calculations are for USD, now convert this amount to Canadian Dollars $12,055,500x1.29=$15,551,595. and yearly revenue should be $186,619,140.
Now we can calculate the profit margin of $186,619,140 and use lower than the company projected EBTIDA 50% = $93,309,570(Company projected EBITDA is 55%)
So, without any P/E ratio, the QSC share price should be somewhere 0.62 cents. Most of the companies in the medical field use a PE Ratio between 5 to 40. You can calculate the P/E Ratio as you like. Whatever P/E Ratio you use or even without any P/E Ratio, QuestCap share price should be much higher.
Now fast forward to the mid-end of January, when Medi-volve should have 100+ tasting centres up and running. At that point, revenue/earning/stock price jumps to more than double. 100x94=9400 test per day with $95 per tests should be generating $893,00 per day and USD 26,790,000 that comes to $34,559,100 Canadian per Month. That is $414,709,200 per year, and the projected EBTIDA calculation with 50% comes to $207,354,600. Per-share EBTIDA profit is about $1.38 per share, and even with a P/E Ratio of 5, Medi-Volve should be trading over $6.90. These projected revenue numbers are based on 100 testing sites, and by the end of April, Medi-volve is planning 740 testing sites.
Per day tests, per site, probably go up as we can see California sites are getting busy now after 3-4 weeks of installation. So, once people know about these testing sites, these sites get busier. Collection sites are at convent locations in the shopping malls parking lots. These revenue projections are going down anytime soon. The medi-volve plan is to add more testing sites to 740 by the end of March into April.
Here are the other revenue streams that add more value.
RESAAS selling testing kits to 500,000 realtors and online in the USA, Australia, and Spain. Sanaty IPS with two locations offering medical service and Covid-19 testing in Columbia S.A.
After Pandemic, Medi-Vole can move to any of these options.
Tasting lab + flu shots and Covid-19 Vaccine
Telehealth: Technology meets health care
All kinds of in vitro testing
Mobile medical services
Retail generic medicines
Sell medical cannabis.
These are my assumption before you buy or sell, do your own due diligence, or read the company projections.